Male Hypogonadism Treatment Algorithm: A Line-by-Line Therapy Guide

At a glance

  • First step / Symptoms plus two early-morning total testosterone values [5]
  • AUA cutoff / Below 300 ng/dL, confirmed on a separate morning [5]
  • Harmonized range / 264 to 916 ng/dL in healthy non-obese men aged 19 to 39 [6]
  • Second step / LH and FSH separate primary from secondary hypogonadism [2][7]
  • If fertility is the goal / Testosterone is avoided; hCG is labeled for selected hypogonadotropic cases [2][3]
  • Approved forms / Injections, gels, nasal gel, oral capsules, pellets, autoinjector [8]
  • On-treatment checks / Testosterone level, hematocrit, blood pressure, prostate risk [2][7][9]

Step 1: Do the symptoms and the lab results agree?

Both major guidelines require the same two elements before any treatment decision: symptoms or signs consistent with testosterone deficiency, and consistently low morning testosterone on more than one measurement [2][5]. The AUA sets a total testosterone below 300 ng/dL as a reasonable cutoff and specifies two measurements on separate occasions, both taken early in the morning; a single low value, or symptoms alone, do not establish the diagnosis [5]. The Endocrine Society asks for a fasting morning total testosterone on an accurate and reliable assay as the initial test, repeated to confirm, and adds free testosterone by equilibrium dialysis or an accurate formula when the total value sits near the lower limit of normal or a condition alters sex hormone-binding globulin [2]. In confirmed deficiency, further testing looks for the cause [2]. The Endocrine Society guideline does not recommend screening the general population [2].

The number itself is less absolute than it looks. When assays from four cohort studies covering 9,054 men were cross-calibrated to a CDC reference method, the total testosterone range in healthy non-obese men aged 19 to 39 ran from 264 to 916 ng/dL — 2.5th to 97.5th percentile, with a 5th percentile of 303, a median of 531 and a 95th percentile of 852 ng/dL [6]. Cut points therefore differ: about 264 ng/dL is the harmonized lower limit of the young healthy range, and 300 ng/dL is the AUA diagnostic cutoff. A substantial part of the variation between cohorts was due to assay differences [6].

Step 2: Primary or secondary — which pattern is it?

FDA testosterone labels lay out the two patterns [7]. Primary hypogonadism is testicular failure — cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals — and these men usually have low testosterone with FSH and LH above the normal range. Hypogonadotropic (secondary) hypogonadism is gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation, and these men have low testosterone with FSH and LH in the normal or low range [7].

Testosterone products are labeled for replacement therapy in both primary and hypogonadotropic hypogonadism [7]. Gonadotropin therapy is labeled for the secondary pattern: hCG is FDA-approved for selected cases of hypogonadotropic hypogonadism in males, meaning hypogonadism secondary to a pituitary deficiency [3][4].

Step 3: The fertility question comes before the first prescription

The Endocrine Society recommends against starting testosterone in men who are planning fertility in the near term [2]. The AUA statement, as quoted by the Sexual Medicine Society of North America, is that exogenous testosterone should not be prescribed to men who are currently trying to conceive, and that men interested in future fertility should discuss effects on spermatogenesis [5]. Exogenous testosterone suppresses sperm production, at large doses through feedback inhibition of pituitary FSH [9].

Step 4: If fertility is the goal — gonadotropins, and what is not approved

Chorionic gonadotropin (Novarel, Pregnyl and generics) is FDA-approved for selected cases of hypogonadotropic hypogonadism in males, for prepubertal cryptorchidism not due to anatomic obstruction, and for ovulation induction in women [3][4]. The same labels state that hCG has not been demonstrated to be effective adjunctive therapy in the treatment of obesity, with no substantial evidence that it adds weight loss beyond caloric restriction [3].

Clomiphene citrate is approved only for ovulatory dysfunction in women; using it in men with low testosterone is off-label [10]. Enclomiphene is not an FDA-approved drug in any form [11]. Anastrozole is approved for breast cancer in postmenopausal women, not for male hypogonadism [12].

Step 5: Testosterone replacement — who it is for, and what exists

FDA states that testosterone products are approved only for men who lack testosterone or have low testosterone together with an associated medical condition, such as testicular failure from genetic problems or chemotherapy, or hypothalamus or pituitary problems; none of the approved products is for men with low testosterone who lack such a condition [1]. Current labels, including the Depo-Testosterone label dated 2026, still carry a Limitation of Use saying safety and efficacy in men with age-related or late-onset hypogonadism have not been established, and in June 2026 FDA asked for that limitation to be removed and for prostate cancer and benign prostatic hyperplasia information to be revised [1][9]. Whether each manufacturer has updated its label yet is not confirmed [1].

Available forms include intramuscular injections (Aveed testosterone undecanoate, Depo-Testosterone cypionate, generic cypionate and enanthate), a subcutaneous autoinjector (Xyosted), topical gels (AndroGel 1% and 1.62%, Testim, Vogelxo), a nasal gel (Natesto), oral testosterone undecanoate capsules (Jatenzo, Tlando, Kyzatrex), subcutaneous pellets (Testopel) and oral methyltestosterone (Methitest); the Androderm patch, Axiron, Fortesta and Striant are marked discontinued [8][13][14][15].

Schedules differ by product. The Depo-Testosterone label suggests 50 to 400 mg every two to four weeks for replacement in the hypogonadal male [9]. The Testim label starts adults at 50 mg of testosterone (one tube) once daily, raised to 100 mg if the morning pre-dose level is below the normal range, and states that Testim is not substitutable with other topical testosterone products [7]. Aveed is available only through a restricted program because of serious pulmonary oil microembolism reactions and anaphylaxis, and patients are observed in the healthcare setting for 30 minutes after each injection [13].

What monitoring looks like after the first prescription

The Endocrine Society advises aiming for mid-normal testosterone concentrations with any approved formulation and monitoring during the first year: symptoms, adverse effects, compliance, serum testosterone, hematocrit and prostate cancer risk [2]. The AUA approach includes monitoring testosterone during treatment to confirm that therapeutic levels are reached and symptoms improve [5].

The Testim label directs checking hematocrit before starting, re-evaluating it 3 to 6 months after starting and then annually, and stopping therapy until hematocrit falls to an acceptable concentration if it becomes elevated [7]. Blood pressure is the other routine measure: the label warns that testosterone can raise blood pressure, which can raise cardiovascular risk over time, and reports a mean 24-hour systolic/diastolic rise of 2.7/1.1 mm Hg at week 16 in 113 patients with acceptable ambulatory recordings [7]. The Depo-Testosterone label likewise asks for periodic blood pressure monitoring, especially in men with hypertension [9].

What the cardiovascular data actually show

TRAVERSE randomized 5,246 men aged 45 to 80 who had symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and existing or high cardiovascular risk to transdermal 1.62% testosterone gel, dose-adjusted to keep levels between 350 and 750 ng/dL, or placebo gel [16]. Mean treatment was 21.7 months and mean follow-up 33.0 months. The first major cardiovascular event — cardiovascular death, nonfatal heart attack or nonfatal stroke — occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo, hazard ratio 0.96 with a 95% CI of 0.78 to 1.17, meeting the trial's noninferiority criterion [16].

That result belongs to that population, that gel and those dose-adjusted levels, not to every product at every dose. A higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism occurred with testosterone in the trial [16]. The Testim label's TRAVERSE data give the specific figures: atrial fibrillation 3.5% versus 2.4%, acute kidney injury 2.3% versus 1.5%, and venous thromboembolism 1.7% versus 1.2% [7].

Boxed warnings are not uniform across the class. FDA's class-wide labeling action of 2/28/2025 removed the language about increased risk of adverse cardiovascular outcomes from the Boxed Warning of all testosterone products and added a blood pressure warning where a product lacked one [17]. What remains is product-specific: Aveed carries a boxed warning for pulmonary oil microembolism and anaphylaxis under its REMS, and the gels Testim and Vogelxo carry one for secondary exposure, because virilization has been reported in children who contact unwashed or unclothed application sites [13][7][17]. Depo-Testosterone and the generic cypionate and enanthate injections have no boxed warning [9][17].

When testosterone should not be started

The Endocrine Society recommends against starting testosterone in men with breast cancer or prostate cancer, a palpable prostate nodule or induration, PSA above 4 ng/mL, PSA above 3 ng/mL in men at increased prostate cancer risk without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, a heart attack or stroke within the last 6 months, or thrombophilia [2]. The guideline's language is 'recommend against,' which is a clinical recommendation, not an FDA contraindication list [2]. The guideline also recommends against using testosterone to improve glycemic control in type 2 diabetes, and suggests against routinely prescribing it to all men aged 65 or older, favoring an individualized discussion for older men with symptoms and consistently low morning levels [2].

Label contraindications add their own detail: Testim is contraindicated in men with known or suspected prostate cancer or breast cancer, and in pregnant women [7]; Depo-Testosterone lists serious cardiac, hepatic or renal disease among its contraindications [9].

Where the algorithm meets sport and the law

Testosterone is a Schedule III controlled substance under the Controlled Substances Act, as both the Depo-Testosterone and Aveed labels state [9][13]. On the WADA 2026 Prohibited List, testosterone is named under S1.1 and prohibited at all times, chorionic gonadotrophin and LH are named under S2.2.1 as testosterone-stimulating peptides in males, clomifene is under S4.2 and anastrozole under S4.1 [18]. The List itself notes that these classes appear in medicines used to treat male hypogonadism, and a prescription alone does not make them permitted in WADA-governed sport — a Therapeutic Use Exemption is required [18]. The 2027 List keeps the same testosterone-stimulating peptide, S1.1 and S4 classifications [19].

Frequently asked questions

How many testosterone tests are needed before treatment starts?
Two, taken on separate mornings. The AUA requires two early-morning total testosterone measurements on separate occasions, with below 300 ng/dL as a reasonable cutoff, and the Endocrine Society requires confirmation by repeating the fasting morning total testosterone [2][5]. The Testim and Depo-Testosterone labels say to confirm the diagnosis before initiating, with serum testosterone measured in the morning on at least two separate days and below the normal range [7][9].
Can a man start testosterone if he wants children soon?
The Endocrine Society recommends against starting testosterone in men planning fertility in the near term, and the AUA statement is that exogenous testosterone should not be prescribed to men currently trying to conceive, because exogenous testosterone suppresses sperm production [2][5][9]. Chorionic gonadotropin is labeled for selected cases of hypogonadotropic hypogonadism in males instead [3].
Is clomiphene an approved treatment for low testosterone?
No. Clomiphene citrate is approved only for ovulatory dysfunction in women, so use in men with low testosterone is off-label, and enclomiphene is not an FDA-approved drug in any form [10][11].
Do all testosterone products carry a heart attack boxed warning?
No. FDA removed the language about increased risk of adverse cardiovascular outcomes from the Boxed Warning of all testosterone products on 2/28/2025 and added a blood pressure warning where a product lacked one [17]. Product-specific boxed warnings remain on Aveed for pulmonary oil microembolism and anaphylaxis and on the gels Testim and Vogelxo for secondary exposure [13][7].
What is checked during the first year of testosterone therapy?
The Endocrine Society lists symptoms, adverse effects, compliance, serum testosterone, hematocrit and prostate cancer risk during the first year [2], and the AUA approach includes on-treatment monitoring to confirm therapeutic levels are reached and symptoms improve [5]. The Testim label directs a hematocrit check before starting, again at 3 to 6 months, then annually, plus periodic blood pressure monitoring [7].

References

Show all 19 referencesHide references
  1. Testosterone Information | FDA.
  2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
  3. U.S. National Library of Medicine, DailyMed. Novarel (chorionic gonadotropin) injection (gonadotrophin, chorionic) prescribing information. Novarel (chorionic gonadotropin) injection (gonadotrophin, chorionic) label
  4. U.S. National Library of Medicine, DailyMed. Pregnyl (chorionic gonadotropin) injection (choriogonadotropin alfa) prescribing information. Pregnyl (chorionic gonadotropin) injection (choriogonadotropin alfa) label
  5. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.
  6. Travison TG, Vesper HW, Orwoll E, Wu F, Kaufman JM, Wang Y, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173.
  7. U.S. National Library of Medicine, DailyMed. Testim (testosterone) gel, Endo prescribing information. Testim (testosterone) gel, Endo label
  8. Drugs@FDA: FDA-Approved Drugs.
  9. U.S. National Library of Medicine, DailyMed. Depo-Testosterone (testosterone cypionate) injection, Pfizer prescribing information. Depo-Testosterone (testosterone cypionate) injection, Pfizer label
  10. U.S. National Library of Medicine, DailyMed. Clomid (clomiphene citrate) tablets prescribing information. Clomid (clomiphene citrate) tablets label
  11. U.S. Food and Drug Administration.
  12. U.S. National Library of Medicine, DailyMed. Arimidex (anastrozole) tablets prescribing information. Arimidex (anastrozole) tablets label
  13. U.S. National Library of Medicine, DailyMed. Aveed (testosterone undecanoate) injection, Endo prescribing information. Aveed (testosterone undecanoate) injection, Endo label
  14. U.S. National Library of Medicine, DailyMed. Testopel (testosterone pellets), Endo prescribing information. Testopel (testosterone pellets), Endo label
  15. U.S. National Library of Medicine, DailyMed. Methitest (methyltestosterone) tablets, Amneal prescribing information. Methitest (methyltestosterone) tablets, Amneal label
  16. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
  17. FDA issues class-wide labeling changes for testosterone products | FDA.
  18. World Anti-Doping Agency.
  19. World Anti-Doping Agency.
Evidence overview for Male Hypogonadism Treatment Algorithm: A Line-by-Line Therapy Guide